ARIX BIOSCIENCE PLC Logo

ARIX BIOSCIENCE PLC

ARIX | IL

Overview

Corporate Details

ISIN(s):
GB00BD045071
LEI:
213800OVT3AHQCXNIX43
Country:
United Kingdom
Address:
1 More London Place, SE1 2AF London
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

ARIX BIOSCIENCE PLC invests in innovative life sciences companies, supporting breakthroughs in biotechnology and healthcare.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for ARIX BIOSCIENCE PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2024-02-12 14:02
Delisting Announcement
Arix Bioscience Plc - Results of 2nd General Meeting
English 123.9 KB
2024-02-12 13:00
Post-Annual General Meeting Information
Scheme Effective
English 28.0 KB
2024-02-12 08:00
Delisting Announcement
Suspension of Trading in Shares
English 19.2 KB
2024-02-07 12:30
M&A Activity
Transaction Update
English 30.8 KB
2024-01-29 14:06
Delisting Announcement
Arix Bioscience Plc - Results of 1st General Meeting
English 61.5 KB
2024-01-29 13:15
Post-Annual General Meeting Information
Results of First General Meeting
English 28.6 KB
2024-01-24 18:30
Major Shareholding Notification
Holding(s) in Company
English 66.9 KB
2024-01-23 11:42
Pre-Annual General Meeting Information
Arix Bioscience Plc - Circular and Notice of Second General Meeting
English 138.5 KB
2024-01-23 08:00
Pre-Annual General Meeting Information
Update on the Scheme and Publication of Notice of Second General Meeting
English 39.2 KB
2024-01-22 08:00
M&A Activity
Update on the Scheme and Resignation of Directors
English 22.4 KB
2024-01-19 08:01
Earnings Release
Financial update on Harpoon Therapeutics acquisition by Merck (MSD)
English 11.7 KB
2024-01-19 08:00
Net Asset Value
Unaudited NAV for December 2023
English 15.1 KB
2024-01-08 18:15
M&A Activity
Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
English 58.4 KB
2024-01-05 08:00
Proxy Solicitation & Information Statement
Publication of Circular and RTW Bio Prospectus
English 43.5 KB
2024-01-04 18:30
Major Shareholding Notification
Holding(s) in Company
English 66.4 KB

Automate Your Workflow. Get a real-time feed of all ARIX BIOSCIENCE PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ARIX BIOSCIENCE PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Initiator Pharma A/S Logo
Clinical-stage firm developing drugs for nervous system disorders like ED & trigeminal neuralgia.
Denmark INIT
Innate Pharma Logo
Clinical-stage biotech developing antibodies that harness NK cells to fight cancer.
France IPH
IntegraGen Logo
Genomics specialist providing analyses & SaaS for cancer/rare diseases to researchers & labs.
France ALINT
Inventiva Logo
Develops oral small molecule therapies for fibrosis, oncology, and lysosomal storage disorders.
France IVA
IRLAB Therapeutics Logo
Developing novel treatments for neurodegenerative conditions like Parkinson's disease.
Sweden IRLAB
Isofol Medical Logo
Clinical-stage biotech developing a drug to enhance chemotherapy efficacy for colorectal cancer.
Sweden ISOFOL
IXICO PLC Logo
AI-powered neuroimaging and biomarker analytics for neurological clinical trials.
United Kingdom IXI
J. Molner AS Logo
A CDRO specializing in generic injectable and topical drugs for the North American market.
Estonia JML
Kadimastem Ltd. Logo
Develops off-the-shelf cell therapies for neurodegenerative and metabolic diseases.
Israel KDST
Kancera Logo
Develops drugs targeting the fractalkine axis for severe inflammation and resistant cancers.
Sweden KAN